tirzepatide gastroparesis case report A newly published series reports that GLP-1 receptor agonists (like semaglutide and tirzepatide) may significantly improve symptoms in patients with mast cell activation syndrome (MCAS), even in those without diabetes or tirzepatide gastroparesis case report 2024

SURPASS-1 compared tirzepatides different doses to placebo and demonstrated superiority in HbA1c reduction with each dose comparison

muciniphila -derived bEVs significantly protect streptozotocin (STZ)-induced diabetic mice by regulating glucose homeostasis, attenuating oxidative stress, and inducing immune tolerance, thereby effectively reducing blood glucose levels and ameliorating insulin resistance

Principal Investigator on ESKETINTRD3004: An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression.

When switching from Ozempic or Wegovy to Strive compounded semaglutide, the milligram dose stays the same

Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications